Long-term protection of macaques against high-dose type D retrovirus challenge after immunization with recombinant vaccinia virus expressing envelope glycoproteins

J Med Primatol. 1993 Feb-May;22(2-3):74-9.

Abstract

Recombinant vaccinia virus expressing the envelope proteins of type D retrovirus-Washington (SRV-2/W) was used to immunize macaques against SRV-2 infection. Four immunized macaques which had resisted a prior low-dose challenge were rechallenged with a high dose (10(6) infectious particles) of SRV-2 two years after being immunized. All four non-immunized control macaques became infected, but the four vaccinated animals resisted this intravenous challenge, as determined by the inability to detect SRV-2 in peripheral blood mononuclear cells and by the lack of seroconversion to new viral antigens.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Base Sequence
  • DNA, Viral / blood
  • DNA, Viral / genetics
  • Immunization
  • Immunoblotting
  • Macaca nemestrina
  • Molecular Sequence Data
  • Polymerase Chain Reaction
  • Retroviruses, Simian / genetics
  • Retroviruses, Simian / immunology*
  • Retroviruses, Simian / isolation & purification
  • Simian Acquired Immunodeficiency Syndrome / immunology
  • Simian Acquired Immunodeficiency Syndrome / microbiology
  • Simian Acquired Immunodeficiency Syndrome / prevention & control*
  • Time Factors
  • Vaccines, Synthetic / administration & dosage
  • Vaccines, Synthetic / pharmacology
  • Vaccinia virus / immunology
  • Viral Envelope Proteins / immunology
  • Viral Vaccines / administration & dosage
  • Viral Vaccines / pharmacology*

Substances

  • DNA, Viral
  • Vaccines, Synthetic
  • Viral Envelope Proteins
  • Viral Vaccines